John A Deford
CIK 1403373 · View on SEC EDGAR ↗
Insider
First SEC filing: Nov. 4, 2024 · Latest: Nov. 4, 2024
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 29 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 31, 2026 | NDSN | A | 84 | $297.78 | $25,014 | 5,902 Direct | +1.44% | Acquired | 8.8% (price as of 2026-08-20) |
| May 26, 2026 | MRVI | A | 46,293 | — | — | 205,478 Direct | +29.08% | Acquired | (price as of 2026-08-20) |
| April 30, 2026 | NDSN | A | 87 | $288.45 | $25,095 | 5,802 Direct | +1.52% | Acquired | 12.4% (price as of 2026-08-20) |
| Jan. 30, 2026 | NDSN | A | 91 | $274.53 | $24,982 | 5,697 Direct | +1.62% | Acquired | 18.1% (price as of 2026-08-20) |
| Jan. 21, 2026 | GMED | A | 15,000 | — | — | 15,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Nov. 1, 2025 | NDSN | A | 822 | $231.95 | $190,663 | 5,587 Direct | +17.25% | Acquired | 39.7% (price as of 2026-08-20) |
| Jan. 23, 2025 | GMED | A | 15,000 | — | — | 15,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Nov. 1, 2024 | NDSN | A | 747 | $249.03 | $186,025 | 4,694 Direct | +18.93% | Acquired | 30.1% (price as of 2026-08-20) |
| Jan. 26, 2024 | GMED | A | 15,000 | — | — | 15,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Nov. 1, 2023 | NDSN | A | 749 | $211.52 | $158,428 | 3,896 Direct | +23.80% | Acquired | 53.2% (price as of 2026-08-20) |
| Oct. 31, 2023 | NDSN | A | 105 | $212.59 | $22,322 | 3,147 Direct | +3.45% | Acquired | 52.5% (price as of 2026-08-20) |
| Sept. 1, 2023 | GMED | A | 15,000 | — | — | 15,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Sept. 1, 2023 | GMED | A | 15,578 | — | — | 15,578 Direct | — | Acquired | (price as of 2026-08-20) |
| Sept. 1, 2023 | GMED | A | 15,000 | — | — | 15,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Sept. 1, 2023 | GMED | A | 15,578 | — | — | 15,578 Direct | — | Acquired | (price as of 2026-08-20) |
| July 31, 2023 | NDSN | A | 89 | $251.61 | $22,393 | 3,034 Direct | +3.02% | Acquired | 28.8% (price as of 2026-08-20) |
| April 28, 2023 | NDSN | A | 104 | $216.31 | $22,496 | 2,937 Direct | +3.67% | Acquired | 49.8% (price as of 2026-08-20) |
| Jan. 31, 2023 | NDSN | A | 92 | $243.30 | $22,384 | 2,818 Direct | +3.37% | Acquired | 33.2% (price as of 2026-08-20) |
| Nov. 1, 2022 | NDSN | A | 730 | $225.93 | $164,929 | 2,726 Direct | +36.57% | Acquired | 43.4% (price as of 2026-08-20) |
| Oct. 31, 2022 | NDSN | A | 100 | $225.00 | $22,500 | 1,996 Direct | +5.27% | Acquired | 44.0% (price as of 2026-08-20) |
| July 29, 2022 | NDSN | A | 97 | $230.99 | $22,406 | 1,891 Direct | +5.41% | Acquired | 40.3% (price as of 2026-08-20) |
| April 29, 2022 | NDSN | A | 104 | $215.69 | $22,432 | 1,790 Direct | +6.17% | Acquired | 50.3% (price as of 2026-08-20) |
| Jan. 31, 2022 | NDSN | A | 96 | $232.54 | $22,324 | 1,678 Direct | +6.07% | Acquired | 39.4% (price as of 2026-08-20) |
| Nov. 1, 2021 | NDSN | A | 608 | $238.43 | $144,965 | 1,582 Direct | +62.42% | Acquired | 35.9% (price as of 2026-08-20) |
| Oct. 29, 2021 | NDSN | A | 79 | $254.21 | $20,083 | 974 Direct | +8.83% | Acquired | 27.5% (price as of 2026-08-20) |
| July 30, 2021 | NDSN | A | 88 | $226.13 | $19,899 | 892 Direct | +10.95% | Acquired | 43.3% (price as of 2026-08-20) |
| April 30, 2021 | NDSN | A | 94 | $211.41 | $19,873 | 804 Direct | +13.24% | Acquired | 53.3% (price as of 2026-08-20) |
| Jan. 29, 2021 | NDSN | A | 85 | $178.99 | $15,214 | 707 Direct | +13.67% | Acquired | 81.1% (price as of 2026-08-20) |
| Nov. 23, 2020 | NDSN | A | 622 | $196.27 | $122,080 | 622 Direct | — | Acquired | 65.1% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 21, 2026 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $94.15 | Jan. 21, 2036 | 15,000 | Acquired |
| Jan. 23, 2025 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $92.42 | Jan. 23, 2035 | 15,000 | Acquired |
| Jan. 26, 2024 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $53.75 | Jan. 26, 2034 | 15,000 | Acquired |
| Sept. 1, 2023 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $54.23 | Sept. 1, 2033 | 15,000 | Acquired |
| Sept. 1, 2023 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $54.23 | Sept. 1, 2024 | 15,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Nov. 25, 2020 | NDSN | No Securities are Beneficially Owned | 0 | Direct |